Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808103 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
A Phase 1 study of Crohn Disease, sponsored by Intralytix.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT03808103 is a Phase 1 study of Crohn Disease that is active but no longer recruiting, run by Intralytix. The registered enrollment target is 30 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03808103, a Phase 1 study of Crohn Disease, is active but no longer recruiting, sponsored by Intralytix.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Bacteriophage preparation
Study Locations (2)
Maryland
- Johns Hopkins Green Spring Station - Lutherville
New York
- Icahn School of Medicine at Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03808103
The ClinicalTrials.gov registry entry for NCT03808103 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (85% lower). The listed sponsor is Intralytix, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03808103 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT03808103 about?
NCT03808103 is a clinical study titled "Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease". This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
What is the current status of trial NCT03808103?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-05-01. Estimated completion is 2026-06-01.
What conditions does trial NCT03808103 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT03808103?
The interventions under investigation include: Placebo (BIOLOGICAL), Bacteriophage preparation (BIOLOGICAL).
Who is sponsoring clinical trial NCT03808103?
This trial is sponsored by Intralytix, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03808103 being conducted?
This trial has 2 study locations across Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
-
Stem Cell Transplantation in Crohn's Disease
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
COMPLETED · Phase 1
-
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.